CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab

Trial Profile

CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms CANARI
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 14 Feb 2017 Planned initiation date changed from 1 Dec 2015 to 1 Mar 2016.
    • 14 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 23 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top